Drug Type Antibody drug conjugate (ADC) |
Synonyms ANTI-NAPI2B, Lifastuzumab vedotin (USAN/INN), DNIB-0600A + [5] |
Target |
Mechanism NaPi-2b inhibitors(Sodium-dependent phosphate transport protein 2B inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11238 | Lifastuzumab vedotin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 2 | US | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | BE | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | CA | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | FR | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | PL | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | ES | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | GB | 06 Feb 2014 | |
Fallopian Tube Carcinoma | Phase 2 | US | - | |
Fallopian Tube Carcinoma | Phase 2 | BE | - | |
Fallopian Tube Carcinoma | Phase 2 | CA | - |